Metabolic abnormalities in impaired glucose tolerance. 1997

J E Gerich
Department of Medicine, Physiology and Pharmacology, University of Rochester School of Medicine, NY 14642, USA.

Impaired glucose tolerance (IGT) is a state in which there is postprandial hyperglycemia (> 7.8 mmol/L, or 140 mg/dL) with minimal elevations of fasting plasma glucose (> 5.5 < 7.8 mmol/L, > 100 < 140 mg/dL). This condition generally precedes the development of diabetes mellitus (DM) by several years. However, in IGT many of the metabolic abnormalities of DM are already present and provide insight into the pathogenesis of DM. Impaired early insulin release is the most consistent defect almost universally observed. Insulin resistance, attributable mainly to obesity, decreased physical fitness, or glucose toxicity, is also often present. The main reason that postprandial hyperglycemia occurs in IGT is impaired suppression of endogenous (hepatic and renal) glucose release; this can be largely explained by impaired early insulin release and impaired suppression of glucagon release. Postprandial glucose disposal is normal or increased, the result of hyperglycemia and delayed hyperinsulinemia. Postabsorptive (fasting) rates of glucose release and disposal and circulating levels of free fatty acids, glycerol, ketone bodies, lactate, and alanine are generally normal.

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D007333 Insulin Resistance Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS. Insulin Sensitivity,Resistance, Insulin,Sensitivity, Insulin
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D003920 Diabetes Mellitus A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
D005934 Glucagon A 29-amino acid pancreatic peptide derived from proglucagon which is also the precursor of intestinal GLUCAGON-LIKE PEPTIDES. Glucagon is secreted by PANCREATIC ALPHA CELLS and plays an important role in regulation of BLOOD GLUCOSE concentration, ketone metabolism, and several other biochemical and physiological processes. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1511) Glucagon (1-29),Glukagon,HG-Factor,Hyperglycemic-Glycogenolytic Factor,Proglucagon (33-61),HG Factor,Hyperglycemic Glycogenolytic Factor
D005947 Glucose A primary source of energy for living organisms. It is naturally occurring and is found in fruits and other parts of plants in its free state. It is used therapeutically in fluid and nutrient replacement. Dextrose,Anhydrous Dextrose,D-Glucose,Glucose Monohydrate,Glucose, (DL)-Isomer,Glucose, (alpha-D)-Isomer,Glucose, (beta-D)-Isomer,D Glucose,Dextrose, Anhydrous,Monohydrate, Glucose
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006943 Hyperglycemia Abnormally high BLOOD GLUCOSE level. Postprandial Hyperglycemia,Hyperglycemia, Postprandial,Hyperglycemias,Hyperglycemias, Postprandial,Postprandial Hyperglycemias
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

J E Gerich
January 1990, Diabetic medicine : a journal of the British Diabetic Association,
J E Gerich
August 1997, Metabolism: clinical and experimental,
J E Gerich
June 2005, Electromyography and clinical neurophysiology,
J E Gerich
May 2012, Journal of the peripheral nervous system : JPNS,
J E Gerich
October 2011, Microcirculation (New York, N.Y. : 1994),
J E Gerich
August 2009, Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology,
J E Gerich
July 2001, Diabetic medicine : a journal of the British Diabetic Association,
J E Gerich
April 2004, American family physician,
Copied contents to your clipboard!